Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.

@article{Boccardo2006SwitchingTA,
  title={Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.},
  author={Francesco M. Boccardo and Alessandra Rubagotti and Pamela Guglielmini and Angela Fini and Giuseppe Paladini and Mario Mesiti and Michela Rinaldini and Simona Scali and Mauro Porpiglia and Chiara Benedetto and Nunzio Restuccia and Franco Buzzi and Roberto Franchi and Bruno Massidda and Vito Distante and Dino Amadori and Piero Sismondi},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2006},
  volume={17 Suppl 7},
  pages={vii10-4}
}
BACKGROUND Tamoxifen, for many years the 'gold standard' in the adjuvant setting for the management of endocrine sensitive early breast cancer, is associated with an increased risk of endometrial cancer and other life-threatening events. Moreover, many women relapse during or after tamoxifen therapy due to the development of resistance. This provided the rationale for a switching trial with anastrozole, the updated results of which are reported here. PATIENTS AND METHODS This trial… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

Similar Papers

Loading similar papers…